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BACKGROUND: Epidermal growth factor receptor (EGFR) mutation status is crucial in treatment selection for non–
small cell lung cancer (NSCLC) patients; however, the detection materials’ availability remains challenging in clinical
practice. In this study, we collected surgical resection tissues, lymph node biopsy, and cytological samples for EGFR
mutation testing and investigated the associations between gene mutation and clinical characteristics. METHODS:
Two hundred and seventy-six NSCLC adenocarcinoma specimens were collected, and highly sensitive amplification
refractory mutation system method was implemented for EGFR mutation detection, with clinicopathologic
characteristics involved in the final analysis. RESULTS: In the total of 276 samples, 96% (265/276) of tumors obtained
evaluable EGFRmutation status, the frequency of mutation was 55.8% (148/265) in all specimens, and three different
type samples shared a comparable successful testing rate: 97.4% (38/39) in surgical tumor tissues, 100% (108/108) in
lymph node biopsy samples, and 92.2% (119/129) in cytological samples. EGFRmutationwas significantly associated
with sex, smoking history, lymph node metastasis status (N stage), primary tumor size, testing tissues origin, and
sample type (P b .05).Multivariate analysis reconfirmed that smoking history and primary tumor size shared significant
correlation with EGFR mutation after adjustment. CONCLUSIONS: Both lymph node biopsy and cytological samples
were suitable surrogates for EGFRmutation detection in NSCLC compared with tumor tissues, gene status should be
detected widely considering the high EGFR mutation rate, and nonsmoking history together with smaller primary
tumor size was an independent indicator of EGFR mutation status.
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Lung cancer causes the majority of cancer-related deaths all over the
world, of which non–small cell lung cancer (NSCLC) comprises nearly
80% to 85% cases [1]; moreover, approximately 75% of patients
presented locally advanced or distant metastasis when diagnosed [2].
Fortunately, with novel biological agents emerging for targeted therapy in
cancer treatment, better response and longer survival were observed in
many clinical trials [3–5]. These small molecular tyrosine kinase
inhibitors (TKIs), such as gefitinib and icotinib, both appeared to have
great advantages when compared with chemotherapy for first-line
treatment in epidermal growth factor receptor (EGFR) mutant
NSCLC patients. Furthermore, detecting EGFR status before TKIs
usage as first-line therapy has been widely accepted [6,7].
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tremendously during the past decade; however, samples’ availabilities
remain challenging. Generally, tumor tissues are optimal for detecting
based on sufficient tumor cells and genome DNA.While nearly 70% of
lung cancer patients were diagnosed using biopsy or cytology specimens
because of the unavailability of surgical tumor tissues in unresectable and
advanced diseases [8,9]. Actually, sufficient diagnostic materials
acquisition remains a problem in all populations; therefore, the necessity
of diagnosis with small biopsy materials and cytological samples appears
more and more important in clinical application. Current data confirm
the cytology testing for EGFR mutation, with a promising concordance
rate between tissues and cytological samples [10–13], which indicates
that small specimens would play as appropriate surrogates in EGFR
detection. As gene mutation testing methods increase dramatically, such
as the second- or third-generation deep sequencing, Sanger sequencing
has been replaced to some extent because of its limitations that include
low sensitivity and longer time consumed [14,15], although it is still
recognized as the “gold standard” in gene detection. Amplification
refractory mutation system (ARMS) is a popular targeted real-time
polymerase chain reaction (PCR)–based method for gene mutation
detection, with a higher sensitivity, more convenient manipulation, and
less turnaround time, which would be proper for EGFR testing especially
in insufficient samples like lymph node biopsy and cytology specimens.
Nowadays, tumor tissues, biopsy, and cytological samples are the
most common diagnostic materials for clinical testing, and EGFR
mutation status appears to have a pivotal role in selecting patients who
are most likely to derive benefits from TKI therapy. However, the
discordance between EGFR mutation tests for several factors such as
variation in tumor cell content and sample size differences remains a
challenge [16,17]. In this study, we collected 276 NSCLC adenocar-
cinoma samples, and the EGFR mutation status was detected by
ARMS. We aimed to investigate the EGFR mutation prevalence in
different sample types; moreover, associations between gene mutations
and clinicopathologic characteristics together with different testing
results among these three samples types were analyzed.Methods
Patients and Samples
From December 2012 to November 2013, a total of 276 NSCLC
adenocarcinoma patients were enrolled in this study with available
testing materials. Eligible patients had pathologically confirmed
NSCLC adenocarcinoma according to American Joint Committee on
Cancer seventh edition criteria and available tumor samples for gene
mutation detection. All patients should be over 18 years old, andwritten
informed consent was obtained from each patient before the study. The
procedure was approved and supervised by the Institutional Review
Board (IRB) of the Cancer Institute/Hospital of Chinese Academy of
Medical Sciences and Peking Union Medical College. Smoking is
defined as at least one cigarette per day or occasionally for at least 1 year,
regardless of past or current status, and patients who had never smoked
cigarettes during their lifetime were recognized as never-smokers.
DNA Extraction and Mutation Analysis
Hematoxylin and eosin staining and histologic analysis were used
to identify the representative malignant cells in each specimen by two
independent pathologists before experiments. Tissue or cell blocks
were cut into 5-μm sections for formalin-fixed, paraffin-embedded
samples, and DNA extraction was performed using the QIAampDNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Extracted DNA was dissolved in 50 μl of
deionized water and stored at −80°C until use. DNA concentration
was measured with a NanoDrop2000 spectrophotometer (Thermo
Scientific, Wilmington, USA) by detecting optical absorbance at 260
nm. Then the EGFR RGQ PCR Kit (Qiagen) was used for EGFR
mutation detection with the ARMS/Scorpion assay, which allows
testing of 29 known mutations for EGFR. PCR results were collected
and analyzed according to the manufacturer's protocols.
Statistical Analysis
Statistical analysis was carried out by the SPSS 17.0 statistical
software (SPSS, Inc., Chicago, IL). Associations between clinico-
pathologic characteristics and EGFR status in all samples types were
evaluated by the chi-square or Fisher exact tests, and only variables
with statistical significance were subjected to final logistic regression
analysis, using a backward stepwise (likelihood ratio) method
with odds ratio (OR) calculated. The two-side significant level was
set at P b .05 through the whole analysis process.
Results
Patients
We have enrolled 276 patients (128 male and 148 female with a
mean age of 56 years) in this study, of which 39 (14.1%) samples
were surgical resection tumor tissues, 108 (39.1%) were derived from
lymph node biopsy, and 129 (46.8%) cases were cytological samples
(98 needle aspiration biopsy, 29 transbronchial endoscopic biopsy,
and 2 pleural effusion samples). The patients’ demographic and
clinicopathologic data are presented in Table 1.
EGFR Mutation Assessment
The EGFR mutation was detected successfully in 265 (96%, 265/
276) samples; 148 (55.8%, 148/265) harbored an EGFR mutation,
of which 68 (25.7%, 68/265) were deletion in exon 19 and 70
(26.4%, 70/265) were L858R in exon 21. T790M mutation was
found in three samples; moreover, two of these coexisted with an
L858R mutation. Other mutant types included G719X in exon 18,
L861Q in exon 21, or combined mutation deletion (exon 19) with
L858R. The spectrum of these mutations was shown in Table 2. All
lymph node biopsy samples were detected successfully (108/108,
100%), whereas the test success rates of tumor tissue samples (38/39,
97.4%) and cytological samples (119/129, 92.2%) were somewhat
lower. These failed 11 samples included 1 surgical resection tumor
tissue and 10 cytological specimens that contained 8 transthoracic
needle biopsy samples and 2 transbronchial endoscopic biopsy
samples. Before we performed the EGFR mutation detection, strict
quality control included DNA concentration, and A260/A280
absorbance ratio was calculated. Nearly all of these samples’ DNA
concentration was lower than 6.0 ng/μl (only one sample’s DNA
concentration was 10.0 ng/μl), and most of the absorbance ratio
appeared aberrant (seven samples with an A260/A280 absorbance
ratio over 2.4 and one sample was lower than 1.7). These 11 samples
did not pass the Qiagen kit positive control; therefore, mutation
detection was not performed. The mutant rates for detected samples
were 63.2% (24/38) in tumor tissues, 46.3% (50/108) in lymph node
biopsy samples, and 62.2% (74/119) in cytological samples,
respectively. And the mutation rates were significantly different in
these three type samples (P = .034,Table 1).
Table 1. Characteristics of 265NSCLC Patients and Association of EGFR Mutations with
Clinicopathologic Parameters
Wild Type Mutation
Characteristics Total No. No. No. P
Sex
Male 120 69 51 b .0001
Female 145 48 97
Age, years
≥56 143 64 79 .572
b56 122 53 69
Smoking history
Ever 101 65 36 b .0001
Never 163 52 111
Missing 1
Initial diagnosis
Locally advanced 89 46 43 .116
Distant metastasis 176 72 104
Tumor stage
IIIa\IIIb 50 28 22 .118
IV 207 84 123
Other * 5 1 4
Missing 3
T stage .068
T1 46 13 33
T2 112 50 62
T3 21 13 8
T4 83 39 44
Missing 3
N stage .040
N0 40 17 23
N1 12 5 7
N2 61 18 43
N3 149 76 73
Missing 3
M stage .089
M0 55 29 26
M1 207 84 123
Missing 3
Primary tumor size
b3 cm 93 30 63 b .0001
N3 to b5 cm 112 40 72
N5 cm 60 41 19
Tissue origin
Lung 130 47 83 .028
Lymph node 121 64 57
Other † 14 6 8
Sample type
Surgical resection tissue 38 14 24 .034
Lymph node biopsy 108 58 50
Cytology samples 119 45 74
* Including four stage II and one stage I patients.
† Including nine pleurae, four bones, and one neck lump.
Table 2. Summary of the EGFR Mutations’ Distribution
No. %
Patients with evaluated test 265 100
Patients with EGFR mutation 148 55.8
Single mutation 141 53.2
Deletion, exon 19 68 25.7
L858R 70 26.4
T790M 1 0.37
G719X 1 0.37
L861Q 1 0.37
Combined mutations 7 2.6
L858R, T790M 2 0.74
L858R, L861Q 1 0.37
L858R, S768I 1 0.37
L858R, Deletion 1 0.37
G719X, Deletion 1 0.37
L861Q, S768I 1 0.37
Patients without EGFR mutation 117 44.2
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EGFR mutation appeared more frequently in female than male
samples (66.9% vs 42.5%), and never-smoking patients shared a higher
mutation status (68.1% vs 35.6%). Although tumor stage did not share
a significant difference, the lymph node metastasis status (N stage)
showed a different EGFR mutation rate. Besides, with tumor size
increased, the EGFR mutation frequency declined. Samples that
originated from lung had a higher EGFR mutation rate than lymph
nodes, bones, and pleura (P b .05, Table 1). Multiple logistic
regression analysis identified that smoking history (P b .0001, OR =
0.289, 95% CI 0.157 to 0.533) and primary tumor size (P = .001,
OR = 0.492, 95% CI 0.329 to 0.736) were still significantly
associated with EGFR mutation status. We did not observe any other
significant association between EGFR mutation and clinicopathologic
characteristics (Table 3).Discussion
In this study, we performed EGFR mutation detection in three
different types of samples by ARMS, and the results showed that all
types of specimens obtained comparable testing success rates (all over
90%). Considering that the acquisition of sufficient materials for
diagnosis and molecular detection in advanced NSCLC patients was
difficult sometimes, it seemed inevitable that small specimens such as
biopsy and cytological samples will be tested for EGFR status.
Previous studies have indicated that cytology samples were suitable in
EGFR mutation detection [11–13]. Herein we collected needle
aspiration biopsy, transbronchial endoscopic biopsy, and pleural
effusion samples to confirm the application of these valid surrogates,
which was also validated by a recent study [18]. EGFR mutation rates
varied significantly in different type of samples. Surgical resection
tissues (63.2%) and cytological samples (62.2%) showed a higher
mutation rate than lymph node biopsy specimens (46.3%), which
was consistent with a recent study [19], although they had a lower
EGFR mutation frequency in all samples. The tendency of EGFR
mutant status was consistent with previous studies. Female and
never-smoking patients shared a higher EGFR mutation frequency
[20,21]. We also found that the primary tumor size was significantly
associated with EGFR mutation. Smaller tumors indicated higher
EGFR mutants. The previous computed tomography scan may
provide clues about gene mutation status; however, because the
sample size was relatively small in our study, the result should be
validated in further studies. Moreover, testing materials that
originated from lung had more EGFR mutations compared with
lymph node or other origins such as pleurae, bones, and neck lump
(EGFR mutation frequency was 63.8%, 47.1%, and 57.1%,
respectively; P = .028;Table 1). The tumor stage did not share
significant association with EGFR mutation in the current study, and
only lymph node metastasis status (N stage) showed a different EGFR
mutation rate, whereas another study reported that patients with stage
IV tumor would be more likely to harbor EGFR mutants (P = .016)
[22]. We thought this difference may have been impacted by different
pathological sample type and region alternations. Future investiga-
tions would provide more knowledge in this controversial issue. The
multiple logistic regression indicated that never-smoking history and
smaller primary tumor size appeared as independent factors in EGFR
mutation status, whereas the tissue origin and other factors did not
share this. Moreover, because tissue origin obtained a statistical
correlation trend with EGFR mutation, although the P value was
Table 3. Multivariate Logistic Regression in NSCLC Patients between EGFR Mutation and
Clinicopathologic Parameters
Characteristics EGFR Mutation
Adjusted OR (95% CI) LRT P value
Sex 0.671 (0.310-1.452) .311
Smoking history 0.289 (0.157-0.533) b .0001
N Stage 0.920 (0.682-1.242) .586
Primary tumor size 0.492 (0.329-0.736) .001
Tissue origin 0.643 (0.387-1.068) .088
Sample type 1.061 (0.672-1.678) .798
LRT: likelihood ratio test; 95% CI: 95% confidence interval.
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sample size in the future would draw a clearer conclusion.
The EGFR mutation frequency varies between ethnicities.
Generally, the Asian population appeared to have more EGFR
mutants than the Western population [22–24]. In our study, the
incidence of EGFR mutation was 55.8%, which was similar to a
recent published study (A prospective, molecular epidemiology study
of EGFR mutations in Asian patients with advanced non–small-cell
lung cancer of adenocarcinoma histology (PIONEER)) in Asian
populations (51.4%) [22]. Although disparities exist in different
populations, the EGFR-TKIs efficacy was demonstrated for both
races [5,25]. Furthermore, regardless of sex, ethnicity, smoking
history, or other clinical risk factors, all patients who are selected for
EGFR inhibitors therapy should receive molecular detection, which
was recommended by three societies in a recently published guideline
[26]. Meanwhile, we have participated in creating the Diagnosis and
Treatment Guideline of Chinese Patients with EGFR Mutation and
ALK Fusion Gene-Positive Non–Small Cell Lung Cancer (2013
Version) based on Chinese characteristics [27]. However, most
NSCLC patients usually suffered from advanced stage when
diagnosed. Samples for detection were available only in small sizes,
such as biopsy and cytological specimens. In the present study, we
confirmed the substitution of biopsy and cytology samples for EGFR
test, which was consistent with previous studies [28,29,10]. With the
limitation of insufficient DNA in small size samples, a more sensitive
method was used in this study.
However, 11 samples did not contribute to the final test, the poor
quality of specimens with lack of tumor cells indicated insufficient
DNA extraction, and we failed to detect the EGFR mutation status
even when using a highly sensitive testing method. These results
implied that cytological samples were more likely to undergo
detection failure for several reasons such as the size of needle and
forceps and the number of biopsies [30,31]. More communications
between clinicians and pathologists would reduce the failure and detection
turnaround time, as clinicians would endeavor to obtain sufficientmaterials
for diagnosis and molecular analysis. Meanwhile, additional feedbacks
would also help provide the rational arrangement of testing procedure and
make maximum use of limited samples [8,9,32,33].
Generally, tumor samples for molecular detection vary with different
intentions. Fresh frozen samples would be a priority when gene mutation
detectionwas planned prospectively, whereas tissue storage for a long time
was required in most cases. To decrease the susceptibility of DNA
degradation and ensure the accuracy of testing results in cut sections, the
choice of fixative was pretty important. In particular, tumor samples fixed
for 8 to 24 hours in neutral-buffered formalin (10%) is preferred, the
fixation time could not surpass this range in avoiding under- or
overfixation, and Bouin or mercury-containing fixatives should beexcluded [34]. Tumor cells enrichment was required for better quality or
more sufficient quantity in formalin-fixed, paraffin-embedded samples,
increasing the reliability of testing results. EGFRmutation could be tested
in different type specimens, such as surgical resection, open biopsy,
endoscopy, transbronchial endoscopic biopsy, and others [11]. In general,
larger sampleswere preferred for the greater amount ofmalignant content,
although small biopsy or cytology specimens were also appropriate for
EGFR detection, particularly if the cell blocks were available [35]. In
addition, because of the possible contamination of extraction or detection
kits, together with the operating procedure were both unpredictable
factors, stricter quality control was extremely necessary before and during
the detection, samples preparation, testing perform. Time consuming
should be taken into consideration together, for the results would guide
the selection of treatment and patients’ welfare[11,16].
Limitations in the present study included the relatively small study
sample size, which would not draw confirmed conclusions in some
issues, and no other detection methods for ensuring the testing results
to decrease the possible false-positive cases. Besides, because different
types of cytology specimens may provide different yields of molecular
analysis based on sampling technique used, then we should realize the
difference during clinical practice [36]. Furthermore, clinical treatment
response and outcomes were not available at present; this information
would bring us a step closer to personalized medicine.
In conclusion, lymph node biopsy and cytological specimens were
suitable surrogates for EGFR mutation detection in NSCLC. The high
EGFRmutation frequency in ChineseNSCLC adenocarcinoma suggested
the necessity for testing in pretreatment patients, and never smoking or
smaller primary tumor size would provide available information for EGFR
mutation status prediction. Finally, emphasis on strict quality control pre-
and posttesting was paramount in considering the consequent treatment
decision for patients.
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